CLINICAL_TRIALS
trial_result
· 2024-01-03
Clinical Trial Update: A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma [Phase 2]
Summary
Phase 2 clinical trial of nivolumab and ipilimumab in patients with resectable malignant peritoneal mesothelioma has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Chicago | Conditions: Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2024-01-03